Patrick J. Stiff
A5013177563- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Polyomavirus and related diseases
- Oral health in cancer treatment
- Mesenchymal stem cell research
- Neutropenia and Cancer Infections
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Cancer therapeutics and mechanisms
- Head and Neck Cancer Studies
- Radiopharmaceutical Chemistry and Applications
- Cancer survivorship and care
- Childhood Cancer Survivors' Quality of Life
- Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- CNS Lymphoma Diagnosis and Treatment
Loyola University Chicago
2016-2025
Loyola University Medical Center
2016-2025
Hospital San Pedro de Alcántara
2023
University of California San Francisco Medical Center
2023
Dana-Farber Cancer Institute
2009-2017
Beth Israel Deaconess Medical Center
2017
University Medical Center
1997-2017
University of Kansas Medical Center
2017
Stanford University
2015
University of California, Davis
2015
In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy.In this multicenter, 2 we enrolled 111 diffuse lymphoma, primary mediastinal or transformed follicular who had disease despite undergoing recommended prior therapy. Patients received target dose 2×106 CAR T cells per kilogram body weight receiving conditioning...
Superficial and systemic fungal infections are a major problem among severely immunocompromised patients who undergo bone marrow transplantation. We performed doubleblind, randomized, multicenter trial in which receiving transplants were randomly assigned to receive placebo or fluconazole (400 mg daily). Fluconazole was administered prophylactically from the start of conditioning regimen until neutrophil count returned 1000 per microliter, toxicity suspected, infection suspected proved.
Patients with neutropenia and persistent fever are often treated empirically amphotericin B or liposomal to prevent invasive fungal infections. Antifungal triazoles offer a potentially safer effective alternative.
Oral mucositis is a complication of intensive chemotherapy and radiotherapy with no effective treatment. We tested the ability palifermin (recombinant human keratinocyte growth factor) to decrease oral mucosal injury induced by cytotoxic therapy.This double-blind study compared effect that placebo on development in 212 patients hematologic cancers; 106 received (60 microg per kilogram body weight day) intravenously for three consecutive days immediately before initiation conditioning therapy...
Purpose This study evaluates the safety and efficacy of plerixafor (AMD3100), a CXCR4 antagonist, in mobilizing hematopoietic stem cells for autologous stem-cell transplantation non-Hodgkin's lymphoma (NHL) patients. Patients Methods is phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study. with requiring an first or second complete partial remission were eligible. received granulocyte colony-stimulating factor (G-CSF; 10 μg/kg) subcutaneously daily up to 8 days....
Sonic hedgehog (SHH), an activating ligand of smoothened (SMO), is overexpressed in > 70% pancreatic cancers (PCs). We investigated the impact vismodegib, SHH antagonist, plus gemcitabine (GV) or placebo (GP) a multicenter phase Ib/randomized II trial and preclinical PC models.
The efficacy of autologous stem-cell transplantation during the first remission in patients with diffuse, aggressive non-Hodgkin's lymphoma classified as high-intermediate risk or high on International Prognostic Index remains controversial and is untested rituximab era.
PURPOSE Adult post-transplantation lymphoproliferative disease (PTLD) has a reported 3-year overall survival (OS) of 35% to 40%. The impact rituximab on the outcome PTLD is not well defined. METHODS We examined clinical features and outcomes among large cohort solid organ transplantation (SOT) -related patients with who were recently treated at four Chicago institutions (from January 1998 2008). Results Eighty identified had median SOT-to-PTLD time 48 months (range, 1 216 months). All...
Purpose Although ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) has been established as the standard of care in patients with advanced Hodgkin lymphoma, newer regimens have investigated, which appeared superior early phase II studies. Our aim was to determine if failure-free survival treated Stanford V regimen compared ABVD. Patients Methods The Eastern Cooperative Oncology Group, along Cancer Leukemia Group B, Southwest Canadian NCIC Clinical Trials conducted this randomized...
Purpose Several open-label randomized studies have suggested that in vivo T-cell depletion with anti-T-lymphocyte globulin (ATLG; formerly antithymocyte globulin-Fresenius) reduces chronic graft-versus-host disease (cGVHD) without compromising survival. We report a prospective, double-blind phase III trial to investigate the effect of ATLG (Neovii Biotech, Lexington, MA) on cGVHD-free Patients and Methods Two hundred fifty-four patients 18 65 years age acute leukemia or myelodysplastic...
Delayed hematopoietic recovery is a major drawback of umbilical cord blood (UCB) transplantation. Transplantation ex vivo-expanded UCB shortens time to recovery, but long-term, robust engraftment by the expanded unit has yet be demonstrated. We tested hypothesis that UCB-derived cell product consisting stem cells for 21 days in presence nicotinamide and noncultured T fraction (NiCord) can accelerate provide long-term engraftment.In phase I trial, 11 adults with hematologic malignancies...
In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at years in patients with refractory large B-cell lymphoma (LBCL). Here, we aimed to assess survival and safety ZUMA-1 after 5 follow-up. Eligible adults LBCL (diffuse lymphoma, primary mediastinal transformed follicular lymphoma) received lymphodepleting chemotherapy followed by axi-cel...
Summary ZUMA‐1 (NCT02348216) examined the safety and efficacy of axicabtagene ciloleucel (axi‐cel), an autologous CD19‐directed chimaeric antigen receptor (CAR)‐T cell therapy, in refractory large B‐cell lymphoma. To reduce treatment‐related toxicity, several exploratory management cohorts were added to ZUMA‐1. Specifically, cohort 6 investigated cytokine release syndrome (CRS) neurologic events (NEs) with prophylactic corticosteroids earlier corticosteroid tocilizumab intervention. CRS NE...
Purpose Despite high initial remission rates, most lymphomas relapse and require further therapy. The mammalian target of rapamycin (mTOR) pathway is a validated in mantle cell lymphoma, but has not been extensively evaluated other lymphomas. Patients Methods We performed phase II trial single-agent temsirolimus 25-mg weekly patients with relapsed aggressive indolent primary objective was overall complete response rate. were stratified by histology: group A (diffuse large B-cell transformed...